CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Diabetes Metab J. 2020;44(4):532-541.   Published online November 22, 2019
DOI: https://doi.org/10.4093/dmj.2019.0093

Excel Download

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
Diabetes & Metabolism Journal. 2020;44(4):532   Crossref logo
Link1 Link2 Link3

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study
Journal of Diabetes Investigation. 2017;9(3):567-572   Crossref logo
Link1 Link2

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
Journal of Diabetes Investigation. 2016;8(2):210-217   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
PLOS ONE. 2016;11(10):e0163350   Crossref logo
Link1

Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Diabetes, Obesity and Metabolism. 2013;15(9):826-832   Crossref logo
Link1 Link2 Link3 Link4

Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Primary Care Diabetes. 2021;15(1):132-137   Crossref logo
Link1 Link2

A Comparison of Twice-Daily Biphasic Insulin Aspart 70/30 and Once-Daily Insulin Glargine in Persons With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Therapy: A Randomized, Open-Label Study
Endocrine Practice. 2011;17(1):41-50   Crossref logo
Link1 Link2 Link3

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes
Diabetes Care. 2012;35(11):2174-2181   Crossref logo
Link1 Link2

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Diabetes mellitus. 2014;17(4):108-119   Crossref logo
Link1 Link2

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Endocrinology and Metabolism. 2019;34(4):382   Crossref logo
Link1 Link2 Link3